Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Amgen, Inc.; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme.

Managing Multiple Myeloma From Newly Diagnosed to Relapsed/Refractory Settings: An Expert Case-Based Discussion

Release Date: September 7, 2021
Expiration Date: September 7, 2022

Activity Overview

Although multiple myeloma (MM) remains incurable, the past 15 years have yielded better clinical outcomes, and response rates have risen as high as 30% with monotherapy and up to 90% with combination therapies. Given the new treatments that offer the potential to improve progression-free survival and overall survival in these patients, keeping up-to-date on emerging clinical data is important for the selection and sequencing of therapy and the management of adverse events.

This activity provides hematologists and oncologists with a review of recent clinical trials to allow them to incorporate new agents and regimens safely and appropriately and thus optimize the management of patients with MM throughout the course of the disease.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Amgen, Inc.; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with MM. Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MM are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • integrate patient-specific factors, risk stratification, and treatment history into individualized treatment plans for patients with newly diagnosed and relapsed/refractory MM
  • evaluate updated results from pivotal trials on current and emerging therapeutic approaches for the treatment of MM across multiple settings
  • develop strategies to identify and mitigate the negative impact of treatment-related toxicities in patients with MM
  • apply practice-changing evidence on single agent/combination approaches and updated guidelines to real-world case scenarios of patients with MM

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Saad Z. Usmani, MD, MBA, FACP
Saad Z. Usmani, MD, MBA, FACP
Director, Plasma Cell Disorder program
Director, Clinical Research in Hematologic Malignancies
Levine Cancer Institute/Atrium Health
Charlotte, NC

Disclosures: Grant Research Support: Amgen Inc.; Array Biopharma Inc.; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals; Merck & Co.; Pharmacyclics, an AbbVie company; Sanofi Genzyme; Seattle Genetics; SkylineDX BV; Takeda Oncology; Consultant: Amgen Inc.; Bristol Myers Squibb; Celgene Corporation; EdoPharma SRL; Genetech, Inc.; Gilead Sciences; GlaxoSmithKline; Janssen Pharmaceuticals; Oncopeptides, Inc.; Sanofi Genzyme; Seattle Genetics; Secura Bio; SkylineDX BV; Takeda Oncology; TeneoBio; Speaker’s Bureau: Amgen Inc., Bristol Myers Squibb, Janssen Pharmaceuticals, Sanofi Genzyme


Surbhi Sidana, MD
Surbhi Sidana, MD
Assistant Professor of Medicine
Director, Myeloma Cellular Immunotherapy
Division of BMT & Cell Therapy
Stanford University
Stanford, CA

Disclosures: Grant Research Support: Amgen Inc., Bristol Myers Squibb, Janssen Pharmaceuticals, Sanofi Genzyme. Consultant: Magenta Therapeutics, Janssen Pharmaceuticals, Bristol Myers Squibb.

Carlyn R. Tan, MD
Carlyn R. Tan, MD
Assistant Attending L1
Department of Medicine
Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Carlyn R. Tan, MD, has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By